These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10161624)

  • 21. California IPA rings up profit with these cap rates.
    Capitation Manag Rep; 1999 Jul; 6(7):109-10, 97. PubMed ID: 10539517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gaining enough market share may be a PSO's biggest challenge.
    Med Netw Strategy Rep; 1998 Mar; 7(3):8-10. PubMed ID: 10181281
    [No Abstract]   [Full Text] [Related]  

  • 23. California IPA wins even in slowing market.
    Capitation Rates Data; 2008 Sep; 13(9):6-7. PubMed ID: 18810936
    [No Abstract]   [Full Text] [Related]  

  • 24. Calif. doc groups on the bleeding edge.
    Jaklevic MC
    Mod Healthc; 1999 Jan; 29(3):34. PubMed ID: 10345450
    [No Abstract]   [Full Text] [Related]  

  • 25. How IPAs are changing.
    Terry K
    Med Econ; 2003 Jun; 80(12):52, 57-8. PubMed ID: 12858786
    [No Abstract]   [Full Text] [Related]  

  • 26. PSOs open the door, but alternate strategies may prove more attractive.
    Med Netw Strategy Rep; 1998 Mar; 7(3):4-7. PubMed ID: 10181279
    [No Abstract]   [Full Text] [Related]  

  • 27. Specialty capitation and effectiveness assessment.
    Lazarovic J
    Physician Exec; 1993; 19(1):32-5. PubMed ID: 10125936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is your organization's market ready for a Medicare PSO?
    Fried I
    Healthc Financ Manage; 1998 Jul; 52(7):48-50. PubMed ID: 10180894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Organizing specialty networks for capitation.
    Krohn RW
    Med Group Manage J; 1996; 43(6):58, 60-2, 64. PubMed ID: 10162878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Provider sponsored organizations: emerging opportunities for growth.
    Fine A; Dowd CE
    Manag Care Q; 1998; 6(3):67-9. PubMed ID: 10182533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A practical approach for analyzing antitrust issues faced by provider networks.
    Ross DC
    J Health Hosp Law; 1997; 30(3):133-45. PubMed ID: 10179111
    [No Abstract]   [Full Text] [Related]  

  • 32. New healthcare economics threaten HIV specialization, patient choice, & quality care.
    James JS
    AIDS Treat News; 1999 Jan; (No 311):1-4. PubMed ID: 11366154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Against all odds, how a large IPA succeeds at capitation.
    McDermott S
    Capitation Manag Rep; 2000 Oct; 7(10):145-50. PubMed ID: 11188070
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk-sharing 'pods' help PHO to manage global capitation.
    Capitation Manag Rep; 1999 Jun; 6(6):84-8. PubMed ID: 10538691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is your organization ready for open access?
    Capitation Manag Rep; 1998 Apr; 5(4):60-1. PubMed ID: 10184891
    [No Abstract]   [Full Text] [Related]  

  • 36. California IPA coasting on these rates, but still tweaking model.
    Capitation Rates Data; 2003 May; 8(5):59-60. PubMed ID: 12803104
    [No Abstract]   [Full Text] [Related]  

  • 37. Physician compensation strategies: one size does not fit all.
    Bhatia R; Stepnick L
    Health Syst Lead; 1997 Dec; 4(11):4-15. PubMed ID: 10175516
    [No Abstract]   [Full Text] [Related]  

  • 38. Defined contribution redux: a view from the front lines.
    Capitation Manag Rep; 2001 Jul; 8(7):97-9. PubMed ID: 11517813
    [No Abstract]   [Full Text] [Related]  

  • 39. Physician-sponsored managed care networks: two suggestions for antitrust reform.
    Bierig JR
    Health Matrix Clevel; 1996; 6(1):115-28. PubMed ID: 10167163
    [No Abstract]   [Full Text] [Related]  

  • 40. Reversing capitation.
    Jaklevic MC
    Mod Healthc; 1997 Jun; 27(23):14-5. PubMed ID: 10167925
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.